The drug, typically taken once a week, would cost between Rs 14,000 and Rs 17,500 per month, depending on the dosage ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India-here's what ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Additionally, GLP-1 agonists such as dulaglutide, semaglutide and liraglutide have been shown to provide cardiovascular benefits. Doctors may also recommend these GLP-1 agonists to reduce the risk ...

In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide. However, despite these ...

Similarly, GLP-1 receptor agonists like Victoza (liraglutide), Ozempic (semaglutide), and Trulicity (dulaglutide) can also aid in weight loss while lowering the risk of cardiovascular disease. With ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...